Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Memo Therapeutics

Memo Therapeutics

## Sitemaps

- [XML Sitemap](https://memo-therapeutics.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Q&A with Matthieu Delince, Director of Oncology Research](https://memo-therapeutics.com/2024/09/17/qa-with-matthieu-delince-director-of-oncology-research/) - 1. Can you talk a bit about how your scientific training and industry experience led to your current role at Memo Therapeutics AG? I’m a bioengineer by training, and the common thread of my career has been the use of novel technologies to better understand diseases and develop new therapies. I started with a PhD
- [Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology](https://memo-therapeutics.com/2026/02/09/memo-therapeutics-ag-enters-into-a-collaboration-and-option-agreement-with-csl-for-development-of-recombinant-polyclonal-igg-technology/) - – Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology– Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by CSL, a license fee, and development and sales milestones of up to CHF 265 million (USD 328 million)– Provides further validation of MTx’s proprietary DROPZYLLA® technology platform Schlieren
- [Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen's Rare Disease pipeline](https://memo-therapeutics.com/2026/07/22/ipsen-completes-acquisition-of-memo-therapeutics-ag-adding-first-in-class-asset-to-ipsens-rare-disease-pipeline/) - PARIS, FRANCE, 22 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody.About potravitugPotravitug is a first-in-class monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. It has shown promising results in
- [Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio](https://memo-therapeutics.com/2026/07/01/ipsen-to-acquire-memo-therapeutics-ag-adding-first-in-class-bk-polyomavirus-antibody-expanding-rare-disease-portfolio/) - – Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody– Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III trial later this year– Ipsen expands rare disease portfolio to include serious and frequent post-transplant infection with no targeted approved treatments PARIS, FRANCE and schlieren/zurich,
- [Memo Therapeutics AG Presents Complete Phase II Clinical Trial Data for Potravitug in Kidney Transplant Recipients at the American Transplant Congress 2026](https://memo-therapeutics.com/2026/06/18/memo-therapeutics-ag-presents-complete-phase-ii-clinical-trial-data-for-potravitug-in-kidney-transplant-recipients-at-the-american-transplant-congress-2026/) - – Complete SAFE KIDNEY II data confirm sustained reduction in viral load and resolution of biopsy-proven BKPyV-associated nephropathy with continued antiviral effect to 38 weeks– Systematic literature review demonstrates the association between longer BKPyV infection duration and increased incidence of BKPyV-associated nephropathy Schlieren / Zurich, Switzerland, 18 June, 2026 – Memo Therapeutics AG (“MTx”), a
- [Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients in an Oral Presentation at the 63rd European Renal Association Congress](https://memo-therapeutics.com/2026/06/05/memo-therapeutics-ag-presents-further-analyses-of-the-phase-ii-trial-results-of-potravitug-for-the-treatment-of-bkpyv-infection-in-kidney-transplant-recipients-in-an-oral-presentation-at-the-63rd-euro/) - – First in class therapeutic antibody, potravitug, for BK polyomavirus infection showed consistent reduction in viral load and biopsy-proven BKPyVAN in a Phase II study in kidney transplant recipients– Propensity Score Matching against large real‑world cohort shows statistically significant viral clearance Schlieren / Zurich, Switzerland, 5 June, 2026 – Memo Therapeutics AG (“MTx”), a late-stage
- [Memo Therapeutics AG Publishes BKPyV Infection Disease Burden Study in the Journal of Patient-Reported Outcomes](https://memo-therapeutics.com/2026/01/09/memo-therapeutics-ag-publishes-bkpyv-infection-disease-burden-study-in-the-journal-of-patient-reported-outcomes/) - – First conceptual model demonstrating the impact of BK polyomavirus on the health-related quality of life of kidney transplant recipients– Study conducted in partnership with Northwestern University and presented at the World Transplant Congress in August 2025 Schlieren / Zurich, Switzerland, 9 January, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique
- [Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union](https://memo-therapeutics.com/2025/12/18/memo-therapeutics-ags-potravitug-granted-orphan-designation-in-the-european-union/) - – Orphan designation confers market exclusivity, regulatory and financial benefits for medicines intended to treat rare diseases– Recognizes both medical plausibility of the initial clinical data and that potravitug targets a life-threatening or chronically debilitating condition, BKPyV infection, which affects fewer than 5 in 10,000 people Schlieren / Zurich, Switzerland, 18 December, 2025 – Memo
- [Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting](https://memo-therapeutics.com/2025/11/07/memo-therapeutics-ag-presents-long-term-follow-up-data-from-its-phase-ii-safe-kidney-trial-of-potravitug-and-real-world-data-on-the-challenges-and-resource-utilization-of-managing-kidney-transplant-re/) - – Long term follow-up data shows a sustained and improved (vs. week 20) benefit of potravitug on BK polyomavirus viral load in kidney transplant recipients at week 38 (study end)– Potravitug was well tolerated, with no treatment related serious adverse events reported Schlieren / Zurich, Switzerland, 7 November, 2025 – Memo Therapeutics AG (“MTx”), a
- [BioBoss podcast with Memo Therapeutics CEO Erik van den Berg](https://memo-therapeutics.com/2025/10/27/bioboss-podcast-with-memo-therapeutics-ceo-erik-van-den-berg/) - Our CEO, Erik van den Berg recently sat down with John Simboli of the BioBoss podcast, where he discussed his career journey from AM-Pharma to Memo Therapeutics and what attracted him to the company – the opportunity to make a meaningful impact on patients’ lives. Drawing on his leadership experience in biotech, Erik explores Memo’s
- [TAVI Interview, Veronica Miller Adjunct Professor at Berkeley Public Health and Director of the Forum for Collaborative Research](https://memo-therapeutics.com/2025/08/25/tavi-interview-veronica-miller-adjunct-professor-at-berkeley-public-health-and-director-of-the-forum-for-collaborative-research/) - 1. Can you please introduce yourself, explain your role and tell us about the mission of the Forum for Collaborative Research, particularly the Transplantation Associated Virus Infections (TAVI) forum.I am Veronica Miller, an immunologist with a PhD and an expert in “regulatory science” with over 24 years of experience currently working at the Forum for
- [An interview with Dr Joseph Gaut, Ladenson Professor of Pathology & Immunology, Washington University School of Medicine](https://memo-therapeutics.com/2025/08/21/an-interview-with-dr-joseph-gaut-ladenson-professor-of-pathology-immunology-washington-university-school-of-medicine/) - Dr Joseph Gaut, Ladenson Professor of Pathology & Immunology at Washington University School of Medicine discusses his thoughts on the recently completed Phase II clinical trial of potravitug, a highly potent therapeutic antibody targeting BK polyomavirus (BKPyV) in kidney transplant recipients. Drawing on his extensive experience working with transplant patients, Dr Gaut explores the trial
- [Memo Therapeutics AG Publishes Phase I Safety, Tolerability, and Pharmacokinetics Study for Neutralizing Antibody Targeting BKPyV Infection in Clinical and Translational Science](https://memo-therapeutics.com/2025/08/19/memo-therapeutics-ag-publishes-phase-i-safety-tolerability-and-pharmacokinetics-study-for-neutralizing-antibody-targeting-bkpyv-infection-in-clinical-and-translational-science/) - – First-in-human, Phase I, randomized, placebo-controlled study, successfully demonstrated safety and tolerability of potravitug in healthy volunteers– The Company recently announced the results from its Phase II placebo-controlled clinical trial of potravitug which showed biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients– Plans are underway to progress potravitug into Phase III development with
- [An interview with Kevin Fowler, Patient Advocate Consultant and Principal, The Voice of the Patient](https://memo-therapeutics.com/2025/08/12/an-interview-with-kevin-fowler-patient-advocate-consultant-and-principal-the-voice-of-the-patient/) - Kevin Fowler, kidney transplant recipient and Principal of The Voice of the Patient, discusses his role as a consultant to Memo Therapeutics, contributing to site engagement and enrollment for the Phase II potravitug trial, as well as forming and executing a patient advisory board. In this interview, Kevin shares his perspective on the encouraging trial
- [An interview with Dr Nadiesda Costa, Associate Professor of Medicine, Medstar Georgetown University Hospital](https://memo-therapeutics.com/2025/08/04/an-interview-with-dr-nadiesda-costa-associate-professor-of-medicine-medstar-georgetown-university-hospital/) - Dr. Nadiesda Costa, Associate Professor of Medicine, Medstar Georgetown University Hospital, discusses her role as Principal Investigator for our Phase II trial for potravitug, a highly potent therapeutic antibody targeting BK polyomavirus (BKPyV) in kidney transplant recipients. In this interview, Dr. Costa shares her thoughts on the encouraging results from the 22-site U.S. trial, focusing
- [An interview with Dr David Wojciechowski, Medical Director of the Kidney Transplantation Program, UT Southwestern Medical Center](https://memo-therapeutics.com/2025/07/30/an-interview-with-dr-david-wojciechowski-medical-director-of-the-kidney-transplantation-program-ut-southwestern-medical-center/) - Dr. David Wojciechowski, Medical Director of the Kidney Transplant Program at the University of Texas Southwestern, discusses his involvement as Site Principal Investigator for our Phase II trial for potravitug, a highly potent therapeutic antibody targeting BK polyomavirus (BKPyV) in kidney transplant recipients. In this interview, David shares his thoughts on the SAFE KIDNEY II
- [Memo Therapeutics AG Announces Phase II Trial Results for Potravitug in Kidney Transplant Recipients with BKPyV Infection](https://memo-therapeutics.com/2025/07/25/memo-therapeutics-ag-announces-phase-ii-trial-results-for-potravitug-in-kidney-transplant-recipients-with-bkpyv-infection/) - – Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients – No safety or tolerability concerns were observed– Supports progression into Phase III development with the potential to transform the treatment landscape for kidney transplant patients with BK polyomavirus infection– Further results from the trial to be presented at the World Transplant
- [Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation](https://memo-therapeutics.com/2025/07/22/memo-therapeutics-ag-publishes-study-on-its-potent-antibody-for-treatment-of-bkpyv-infection-in-kidney-transplantation/) - Novel antibody, potravitug, demonstrates high neutralization of all BKPyV serotypes with potential to transform treatment for kidney transplant recipients with BKPyV infection Schlieren / Zurich, Switzerland, 22 July, 2025 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, has published preclinical data
- [Q&A with William Fitzsimmons, Transplant Therapeutics Consortium Executive Committee Member](https://memo-therapeutics.com/2025/07/10/qa-with-william-fitzsimmons-transplant-therapeutics-consortium-executive-committee-member/) - 1. Please introduce yourself and tell us about your background spanning both academia and industry, particularly your role in the Transplant Therapeutics Consortium (TTC). I am William Fitzsimmons, a pharmacist by training. My career started at an academic medical center in Chicago, Rush University, where I was involved in bone marrow transplant and liver transplantation.
- [Memo Therapeutics AG to Present Interim Phase II Results of Potravitug for the Treatment of BKV Infection in Kidney Transplant Recipients in a Late Breaking Oral Presentation at the World Transplant Congress](https://memo-therapeutics.com/2025/06/19/memo-therapeutics-ag-to-present-interim-phase-ii-results-of-potravitug-for-the-treatment-of-bkv-infection-in-kidney-transplant-recipients-in-a-late-breaking-oral-presentation-at-the-world-transplant-c/) - Schlieren / Zurich, Switzerland, 19 June, 2025 – Memo Therapeutics AG ( “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced that its late breaking abstract has been accepted for an oral presentation at the World Transplant Congress (“WTC”) in San Francisco taking place
- [Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration](https://memo-therapeutics.com/2025/06/11/memo-therapeutics-ag-publishes-study-in-frontiers-in-pharmacology-demonstrating-therapeutic-antibody-transcytosis-across-the-kidney-barrier-after-intravenous-administration/) - Results demonstrate that intravenously administered therapeutic IgG antibodies can be detected in urine, supporting the conclusion that these antibodies are capable of crossing the kidney endothelial barrierThis proof-of-concept study provides compelling support for the selected dosing regimen of MTx’s investigational BK polyomavirus-neutralizing antibody Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or
- [World Kidney Day Interview, Richard Knight](https://memo-therapeutics.com/2025/03/13/world-kidney-day-interview-richard-knight/) - 1. Please introduce yourself to our audience and share with us a bit about your journey with kidney disease. Good day everyone, I’m Richard Knight, currently a Lecturer at Bowie State University’s College of Business where I’ve taught for over 20 years, and the immediate Past President of the American Association of Kidney Patients (AAKP).My
- [Q&A with Karin Hehenberger, President & Founder of Lyfebulb & Chief Medical Officer of Patient Care America](https://memo-therapeutics.com/2025/02/11/qa-with-karin-hehenberger-president-founder-of-lyfebulb-chief-medical-officer-of-patient-care-america/) - BackgroundLyfebulb, founded in 2014 by Karin Hehenberger, is an organisation with a mission to reduce the burden of chronic disease through the power of the patient. In March 2024, it became part of Patient Care America, where Karin now serves as both Chief Medical Officer of Patient Care America and President of Lyfebulb. A key
- [Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy](https://memo-therapeutics.com/2024/08/27/alex-bastian-joins-memo-therapeutics-ag-as-vp-commercial-strategy/) - Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate potravitug entering Phase III trial Schlieren / Zurich, Switzerland, 27 August, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique human immune responses into superior medicines to treat
- [Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer](https://memo-therapeutics.com/2024/11/04/frits-van-alphen-new-cdo-at-memo/) - Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren / Zurich, Switzerland, 4 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer,
- [Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients](https://memo-therapeutics.com/2024/11/01/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-potravitug-for-treatment-of-bk-viremia-in-kidney-transplant-patients/) - Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the last patient has been enrolled in its 22-site U.S. Phase II trial for its BK polyomavirus (“BKV”)-neutralizing antibody, potravitug.With topline data
- [Q&A with Kevin Fowler, Patient Advocate Consultant and Principal, The Voice of the Patient](https://memo-therapeutics.com/2024/10/24/qa-with-kevin-fowler-patient-advocate-consultant-and-principal-the-voice-of-the-patient/) - 1. What influenced your transition from a career in the pharmaceutical industry to patient advocacy? Professionally, I came to a fork in the road in my career. I took inventory of my strengths and assessed the marketplace. I concluded that my professional experience combined with my lived experience with kidney disease provided unique value outside
- [Memo Therapeutics AG Appoints Erik Van Den Berg as Chief Executive Officier](https://memo-therapeutics.com/2023/11/16/memo-therapeutics-ag-appoints-erik-van-den-berg-as-chief-executive-officier/) - Mr. van den Berg is an industry veteran with proven track record in building high-performance teams and delivering on strategic and financial transactions Schlieren / Zurich, Switzerland – November 16, 2023 – Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the appointment of Erik van den Berg as Chief
- [Memo Therapeutics AG Strengthens Management Team](https://memo-therapeutics.com/2024/02/05/memo-therapeutics-ag-strengthens-management-team/) - Appoints Kristie B. Clemmer as VP Clinical Operations and Dr. Maartje Verschuur as VP CMC and Supply Chain Management Schlieren / Zurich, Switzerland, February 5, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies for viral infections and oncology, announced today that it has strengthened its senior team with
- [Memo Therapeutics AG Increase Series C Financing to CHF 45 Million](https://memo-therapeutics.com/2024/05/07/memo-therapeutics-increase-series-c-financing-to-chf-45-million/) - Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investorsProceeds will be used to expand Phase II of best-in-class anti-BK polyomavirus antibody to become the largest study ever conducted for BK polyomavirus infection in kidney transplantation Schlieren / Zurich, Switzerland, 7 May, 2024 – Memo Therapeutics AG (or
- [Q&A with Dr. Simone Schmitt, VP Technology & Operations](https://memo-therapeutics.com/2024/09/03/qa-with-dr-simone-schmitt-vp-technology-operations/) - 1. Can you talk a bit about your personal journey in antibody discovery and how this led you to the role at Memo Therapeutics AG MTx ? I’ve had an interest in human diseases and drug development for a long time. My academic journey began with a degree in molecular biology before completing a PhD
- [Memo Therapeutics AG Announces Positive Phase I Data With AntiBKV For Treatment Of BKV Infection In Renal Transplant Patients](https://memo-therapeutics.com/2023/01/24/memo-therapeutics-ag-announces-positive-phase-i-data-with-antibkv-for-treatment-of-bkv-infection-in-renal-transplant-patients/) - Clinical trial met primary endpoint of safety and tolerability IND submission planned in Q1 2023 to initiate U.S. multicenter study Schlieren / Zurich, Switzerland – January 24, 2023 – Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announced today positive safety and tolerability data from a Phase I clinical
- [Memo Therapeutics AG Receives FDA Fast Track Designation For AntiBKV As Treatment Of BKV Infection In Renal Transplant Patients](https://memo-therapeutics.com/2023/05/02/memo-therapeutics-ag-receives-fda-fast-track-designation-for-antibkv-as-treatment-of-bkv-infection-in-renal-transplant-patients/) - Pivotal U.S. phase II/III clinical trial has started recruiting patients AntiBKV antibody therapeutic has potential to be first- and best-in-class treatment; scheduled to be launched in 2025 Schlieren / Zurich, Switzerland – May 2, 2023 – Memo Therapeutics AG (“MTx”), a biotech company developing best-in-class therapeutic antibodies, announced today that the U.S. Food and Drug
- [Memo Therapeutics AG Starts U.S. Pivotal Phase II/III Clinical Trial With AntiBKV For Treatment Of BKV Infection In Renal Transplant Patients](https://memo-therapeutics.com/2023/06/22/memo-therapeutics-ag-starts-u-s-pivotal-phase-ii-iii-clinical-trial-with-antibkv-for-treatment-of-bkv-infection-in-renal-transplant-patients/) - AntiBKV has potential to be first- and best-in-class treatment representing the sole option for large and growing number of patients Interim data expected by the end of 2023; on track to reach patients in 2025 Schlieren / Zurich, Switzerland – June 22, 2023 – Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic
- [Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients](https://memo-therapeutics.com/2023/11/02/memo-therapeutics-ag-raises-chf-25-million-series-c-financing-to-complete-phase-ii-clinical-development-of-antibkv-for-bkv-infection-in-renal-transplant-patients/) - Series C led by Pureos BioventuresFinancing to support completion of a Phase II trial of AntiBKV and to prepare manufacturing of drug for Phase III Schlieren / Zurich, Switzerland – November 2, 2023 – Memo Therapeutics AG (“MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies, announced today the closing of a CHF25 million Series
- [Memo Therapeutics AG Appoints Paul Carter as Chairperson](https://memo-therapeutics.com/2024/07/08/memo-therapeutics-ag-appoints-paul-carter-as-chairperson/) - Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKVExtensive public and private market experience following executive positions in numerous biopharma companies Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and

## Pages

- [Homepage](https://memo-therapeutics.com/) - Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
- [Latest News](https://memo-therapeutics.com/latest-news/) - Stay up-to-date and get all the latest news and information and company news at Memo Therapeutics AG. Find out more.
- [Further Information](https://memo-therapeutics.com/further-information/) - Keep up-to-date and in the know with our selected publications from BKV, Oncology and Dropzylla and more. Find out more.
- [Contact us](https://memo-therapeutics.com/contact-us/) - If you would like to contact Memo Therapeutics AG you can find our contact details and instructions on how to find us and a contact form for specific enquiries.
- [Expanded Access Policy](https://memo-therapeutics.com/expanded-access-policy/) - Expanded Access Policy Memo Therapeutics AG (“MTx”) is committed to developing promising new therapies to address the unmet medical needs of patients suffering from rare and seriously debilitating diseases.We currently have late-stage investigational medicines in our product pipeline for the treatment of BKPyV infection in kidney transplant recipients. Our goal is to provide access to
- [About us](https://memo-therapeutics.com/about-us/) - Memo Therapeutics is a late-stage biotech company developing best-in-class therapeutic antibodies to transform lives of patients with viral infections & cancer.
- [BKV](https://memo-therapeutics.com/bkv/) - Our most advanced program Potravitug, a monoclonal antibody, targets BK viremia (BKV) in kidney transplant recipients. BK viremia is caused by the BK virus.
- [Privacy Policy](https://memo-therapeutics.com/privacy-policy/) - Discover how we protect your data with our privacy policy as we develop cutting-edge therapeutic antibodies
- [Cookie Policy](https://memo-therapeutics.com/cookie-policy/) - Learn about our cookie policy and how we use cookies to enhance your experience as we develop therapeutic antibodies for viral infections and cancer.
- [Terms and Conditions](https://memo-therapeutics.com/terms-and-conditions/) - Review our terms and conditions as we innovate best-in-class therapeutic antibodies to transform the lives of patients with viral infections and cancer.

## Events

- [The World Transplant Congress](https://memo-therapeutics.com/event/jefferies-healthcare-conference-2-2/) - The World Transplant Congress serves as a platform for experts from around the globe to meet and share research, discuss advancements, and address challenges in organ transplantation and is organized jointly by the American Society of Transplant Surgeons (ASTS), the American Society of Transplantation (AST), and The Transplantation Society (TTS).
- [BIO Europe](https://memo-therapeutics.com/event/bio-europe-2/) - BIO Europe is a place to connect with top biotech innovators, investors, and industry leaders from around the world that will take place 3-5 November 2025 in Vienna, Austria.
- [Cutting Edge of Transplantation 2025](https://memo-therapeutics.com/event/cutting-edge-of-transplantation-2025/) - The Cutting Edge of Transplantation 2025 will take place 22nd February 2025 in Arizona, USA.
- [ESMO Congress](https://memo-therapeutics.com/event/esmo-congress-2/) - The ESMO Congress is a highly influential global oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. It will take place 17-21 October 2025 in Berlin, Germany.
- [Jefferies Healthcare Conference](https://memo-therapeutics.com/event/jefferies-healthcare-conference-2/) - The Jefferies 2025 London Healthcare Conference will take place 18-20 November 2025 in London, UK.
- [Festival of Biologics](https://memo-therapeutics.com/event/festival-of-biologics/) - The Festival of Biologics brings together pharma & biotech, academics, research institutes, regulators, patient groups and payers together with their partners across the value chain, taking place 30 September-2 October 2025 in Basel, Switzerland.
- [ASN Kidney Week](https://memo-therapeutics.com/event/asn-kidney-week-2/) - The world’s premier nephrology meeting, ASN Kidney Week 2025 will take place 5-9 November in Houston, Texas.
- [Sachs Annual Biotech in Europe Forum](https://memo-therapeutics.com/event/sachs-annual-biotech-in-europe-forum/) - The Sachs 25th Annual Biotech in Europe Forum will take place September 2025 in Basel, Switzerland.
- [CICON](https://memo-therapeutics.com/event/cicon/) - The CRI-ENCI Ninth International Cancer Immunotherapy Conference will take place 10-13 September 2025 in Utrecht, The Netherlands.
- [World Transplant Congress](https://memo-therapeutics.com/event/world-transplant-congress/) - With the latest research and breakthroughs in the field of transplantation, WTC 2025 will take place 2-6 August 2025, in San Fransisco, California.
- [BIO International Convention](https://memo-therapeutics.com/event/bio-international-convention/) - The largest and most comprehensive event for biotechnology, BIO International Convention will take place 16-19 June 2025, in Boston, Massachusetts.
- [BioEquity Europe](https://memo-therapeutics.com/event/bioequity-europe/) - Celebrating its 25th year, Bio€quity Europe is where CEOs and investors gather to network, partner, and debate critical issues facing the biotech industry. It will take place 12-14 May 2025 in Bruges, Belgium.
- [Swiss Biotech Day 2025](https://memo-therapeutics.com/event/swiss-biotech-day-2025/) - A premier biotechnology conference, Swiss Biotech Day will take place 5-6 May 2025 in Basel, Switzerland.
- [LSX World Congress](https://memo-therapeutics.com/event/lsx-world-congress/) - The LSX World Congress gathers senior life science industry decision-makers from the world's most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs. It will take place 29-30 April 2025 in London, UK.
- [AACR Annual Meeting](https://memo-therapeutics.com/event/aacr-annual-meeting/) - The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. It will take place 25-30 April 2025 in Chicago, Illinois.
- [BIO Europe Spring](https://memo-therapeutics.com/event/bio-europe-spring/) - BIO Europe Spring will take place 17-19 March 2025 in Milan, Italy, connecting Europe’s top innovation centers with the global life sciences industry to cultivate thriving, strategic partnerships
- [BIO Europe](https://memo-therapeutics.com/event/bio-europe/) - Experience BIO-Europe and connect with delegates spanning the global life science ecosystem to propel dealmaking and innovation Join over 5,500 attendees, representing more than 2,800 companies and over 60 countries
- [ASN Kidney week](https://memo-therapeutics.com/event/asn-kidney-week/) - The ASN Kidney Week 2024 Conference will take place 24-27 October 2024 in San Diego, California.
- [Sachs 24th Annual Biotech in Europe Forum](https://memo-therapeutics.com/event/sachs-24th-annual-biotech-in-europe-forum/) - We are pleased to announce that the 24th Annual Biotech in Europe Forum will take place on the 25th - 26th of September 2024 at the Mövenpick Hotel Basel. The event will be part of the Sachs Autumn Life Sciences Week, which will also incorporate the 11th Annual HealthTech Investment Forum.
- [ESMO Congress](https://memo-therapeutics.com/event/esmo-congress/) - The ESMO Congress 2024 will take place 13-17 September 2024 in Barcalona, Spain.
- [Test Event 3 (Past)](https://memo-therapeutics.com/event/test-event-3-past/) - Tellus elementum sagittis vitae et. Leo duis ut diam quam nulla porttitor massa id neque. Nunc mattis enim ut tellus elementum sagittis vitae et leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Enim nunc faucibus a pellentesque sit amet porttitor eget. Nunc id
- [Test Event 2 (Past)](https://memo-therapeutics.com/event/test-event-2-past/) - Tellus elementum sagittis vitae et. Leo duis ut diam quam nulla porttitor massa id neque. Nunc mattis enim ut tellus elementum sagittis vitae et leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Enim nunc faucibus a pellentesque sit amet porttitor eget. Nunc id
- [Test Event 1 (Past)](https://memo-therapeutics.com/event/test-event-1-past/) - Tellus elementum sagittis vitae et. Leo duis ut diam quam nulla porttitor massa id neque. Nunc mattis enim ut tellus elementum sagittis vitae et leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Enim nunc faucibus a pellentesque sit amet porttitor eget. Nunc id
- [Event title goes here over a few lines if required on the site](https://memo-therapeutics.com/event/event-title-goes-here-over-a-few-lines-if-required-on-the-site/) - Tellus elementum sagittis vitae et. Leo duis ut diam quam nulla porttitor massa id neque. Nunc mattis enim ut tellus elementum sagittis vitae et leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Enim nunc faucibus a pellentesque sit amet porttitor eget. Nunc id

## Investors

- [Pureos Bioventures](https://memo-therapeutics.com/investor/pureos-bioventures/)
- [YSIOS Capital](https://memo-therapeutics.com/investor/ysios-capital/)
- [Kurma Partners](https://memo-therapeutics.com/investor/kurma-partners/)
- [Adjuvant Capital](https://memo-therapeutics.com/investor/adjuvant-capital/)
- [Zurcher Kantonalbank](https://memo-therapeutics.com/investor/zurcher-kantonalbank/)
- [Vesalius Biocapital](https://memo-therapeutics.com/investor/vesalius-biocapital/)

## Partners

- [](https://memo-therapeutics.com/partner/551/) - Placeholder
- [Ono Pharmaceutical](https://memo-therapeutics.com/partner/ono-pharmaceutical/)
- [University Hospital of Zurich](https://memo-therapeutics.com/partner/university-hospital-of-zurich/)
- [University Hospital of Bern](https://memo-therapeutics.com/partner/university-hospital-of-bern/)
- [University of Basel](https://memo-therapeutics.com/partner/university-of-basel/)
- [ETH Zurich](https://memo-therapeutics.com/partner/eth-zurich/)
- [TTC](https://memo-therapeutics.com/partner/ttc/)
- [TAVI Forum](https://memo-therapeutics.com/partner/tavi-forum/)

## Publications

- [Development of a conceptual model of BKV impacts on health-related quality of life in kidney transplant recipients: a qualitative study](https://memo-therapeutics.com/publication/development-of-a-conceptual-model-of-bkv-impacts-on-health-related-quality-of-life-in-kidney-transplant-recipients-a-qualitative-study/) - BK virus (BKV) is a common latent virus that can reactivate in 8 kidney transplant recipients due to immunosuppressive therapy, potentially 9 leading to graft dysfunction or loss.
- [First-In-Human, Randomized, Placebo-Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults](https://memo-therapeutics.com/publication/first-in-human-randomized-placebo-controlled-sad-and-mad-trial-to-evaluate-safety-tolerability-and-pk-pd-modeling-of-potravitug-in-healthy-adults/) - This paper highlights the Phase I clinical data, including safety, tolerability, and pharmacokinetics, for potravitug, a highly potent human monoclonal antibody targeting BK polyomavirus.
- [A Highly Potent Human Antibody Neutralizing All Serotypes of BK Polyomavirus](https://memo-therapeutics.com/publication/a-highly-potent-human-antibody-neutralizing-all-serotypes-of-bk-polyomavirus/) - This study describes the discovery and characterization of a highly-potent BK polyomavirus-neutralizing antibody, identified from a kidney transplant recipient who displayed rapid clearance of high-level BKPyV-DNAemia.
- [Quantification of endogenous and therapeutic IgG crossing the kidney barrier from bloodstream to urine](https://memo-therapeutics.com/publication/quantification-of-endogenous-and-therapeutic-igg-crossing-the-kidney-barrier-from-bloodstream-to-urine/) - This study investigates the biodistribution of a therapeutic antibody from serum to urine across the kidney endothelial barrier, contextualizing the findings with existing literature.
- [Burden of BK Virus Infection and BK Virus-Associated Nephropathy in Kidney Transplant Recipients: Scoping Review Reveals Gaps in Patient-Centered Research](https://memo-therapeutics.com/publication/burden-of-bk-virus-infection-and-bk-virus-associated-nephropathy-in-kidney-transplant-recipients-scoping-review-reveals-gaps-in-patient-centered-research/) - This poster highlights a scoping literature review which aimed to synthesize the current evidence on burden of BKV infection and BKVN in kidney transplant recipients, with a focus on identifying patient-centered research and outcomes.
- [Neutralizing Antibody–Mediated Response and Risk of BK Virus–Associated Nephropathy](https://memo-therapeutics.com/publication/neutralizing-antibody-mediated-response-and-risk-of-bk-virus-associated-nephropathy/) - This study found that high neutralizing antibody titers against the replicating strain reduce the risk of BK viremia, suggesting a role of neutralizing antibodies in managing BK viremia.
- [BK Virus Infection and BK-Virus-Associated Nephropathy in Renal Transplant Recipients](https://memo-therapeutics.com/publication/bk-virus-infection-and-bk-virus-associated-nephropathy-in-renal-transplant-recipients/) - BK polyomavirus (BKV) is highly infective, often causing asymptomatic infections in childhood and remaining latent in kidney cells. In renal transplant recipients, BKV can reactivate, leading to nephropathy and significant graft loss, with current treatments focusing on reducing immunosuppression and emphasizing the importance of early diagnosis and surveillance for better outcomes.
- [The Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation](https://memo-therapeutics.com/publication/the-second-international-consensus-guidelines-on-the-management-of-bk-polyomavirus-in-kidney-transplantation/) - BKV-nephropathy remains a major cause of premature kidney allograft failure, necessitating proactive screening, monitoring, and timely immunosuppression reduction. The updated Second International Consensus Guidelines review significant advances and provide updated recommendations, emphasizing the need for further research and randomized clinical trials.
- [Discovery of superior functional antibodies from comprehensive recombinant antibody repertoires](https://memo-therapeutics.com/publication/discovery-of-superior-functional-antibodies-from-comprehensive-recombinant-antibody-repertoires/) - This poster, presented 2022 at PEGS Europe, describes the discovery of superior functional antibodies using Dropzylla, a microfluidic-based single-cell analysis platform, highlighting its comprehensive antibody repertoire coverage and high-throughput screening capabilities for therapeutic applications.
- [Antibody repertories of tumor-infiltrating B cells](https://memo-therapeutics.com/publication/antibody-repertories-of-tumor-infiltrating-b-cells/) - This poster, presented 2023 at CICON, details the diverse antibody repertoires of tumor-infiltrating B cells, highlighting their potential for anti-tumor activity and the use of the Dropzylla platform for comprehensive analysis and biobanking.
- [Fast-Track Discovery of SARS-CoV-2-Neutralizing Antibodies from Human B Cells by Direct Functional Screening](https://memo-therapeutics.com/publication/fast-track-discovery-of-sars-cov-2-neutralizing-antibodies-from-human-b-cells-by-direct-functional-screening/) - The DROPZYLLA® platform was used in early 2020 to rapidly generate SARS-CoV-2-specific antibodies from convalescent COVID-19 donors, yielding neutralizing antibodies within 3-6 weeks. One antibody, MTX-COVAB, showed strong efficacy against all known variants at that time and went into clinical development.
- [The economic burden of kidney graft failure in the United States](https://memo-therapeutics.com/publication/the-economic-burden-of-kidney-graft-failure-in-the-united-states/) - The economic burden of kidney graft failure is significant. Reducing graft failure would improve quality of life, extend patient survival, and result in reduced health care spending.
- [Prevalence, Risk Factors, Treatment, and Overall Impact of BK Viremia on Kidney Transplantation](https://memo-therapeutics.com/publication/prevalence-risk-factors-treatment-and-overall-impact-of-bk-viremia-on-kidney-transplantation/) - BK viremia is a significant issue in renal transplantation, with male sex, older age, and maintenance steroids identified as key risk factors. The study found that BKV negatively impacts graft and patient survival, highlighting the need for a unified treatment approach.
- [Advancing Patient-Centered Research: Enabling the Patient Voice to Be Heard](https://memo-therapeutics.com/publication/advancing-patient-centered-research-enabling-the-patient-voice-to-be-heard/) - The article discusses the importance of incorporating the patient voice in patient-centered research, particularly in the context of kidney diseases, to improve healthcare outcomes and ensure that patient perspectives and needs are adequately addressed.
- [Tumor-reactive antibodies evolve from non-binding and autoreactive precursors](https://memo-therapeutics.com/publication/tumor-reactive-antibodies-evolve-from-non-binding-and-autoreactive-precursors/) - Tumour infiltrating B cells secrete antibodies that bind cancer cells and show functional anti-tumour activity in ovarian cancer.
- [Antibodies against Endogenous Retroviruses Promote Lung Cancer Immunotherapy](https://memo-therapeutics.com/publication/antibodies-against-endogenous-retroviruses-promote-lung-cancer-immunotherapy/) - Cancer derived antibodies have anti-tumour activity and promote response to lung cancer immunotherapy
- [The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma](https://memo-therapeutics.com/publication/the-single-cell-immunogenomic-landscape-of-b-and-plasma-cells-in-early-stage-lung-adenocarcinoma/) - B cells are associated with a favourable cancer prognosis in lung cancer
- [Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities](https://memo-therapeutics.com/publication/tumour-infiltrating-b-cells-immunological-mechanisms-clinical-impact-and-therapeutic-opportunities/) - In most cancer indications, B cells are associated with a favourable prognostic outcome.
- [Tertiary Lymphoid Structures in the Era of Cancer Immunotherapy](https://memo-therapeutics.com/publication/tertiary-lymphoid-structures-in-the-era-of-cancer-immunotherapy/) - B cells develop within tumours in tertiary lymphoid structures.

## Team Testimonials

- [Matthieu Delince](https://memo-therapeutics.com/team-testinonial/matthieu-delince/)
- [Simone Schmitt](https://memo-therapeutics.com/team-testinonial/simone-schmitt/)

## Categories

- [Pharmaceutical Companies](https://memo-therapeutics.com/category/pharmaceutical-companies/)
- [Research Universities](https://memo-therapeutics.com/category/research-universities/)
- [Industry Forums](https://memo-therapeutics.com/category/industry-forums/)
- [Nephrology](https://memo-therapeutics.com/category/research-universities/nephrology/)
- [Oncology](https://memo-therapeutics.com/category/research-universities/oncology/)
- [Blog Posts](https://memo-therapeutics.com/category/blog-posts/)
- [Past Events](https://memo-therapeutics.com/category/past-events/)
- [Archived](https://memo-therapeutics.com/category/archived/)